Researchers Develop Animal Free Methods for Testing Chemical Compounds for Allergens
News Apr 08, 2013
As of march 2013 there is a ban in the European Union (EU) on animal testing of ingredients for cosmetics.
The ban applies to all new cosmetics and their ingredients sold in the EU, regardless of where in the world testing on animals was carried out.
The 27 EU countries have had a ban on such tests in place since 2009, but despite this, cosmetics firms were allowed to continue testing on animals for the most complex human health effects, such as toxicity which might lead to cancer. However, those tests now come under the ban too.
This controversy has resulted in research to produce new, animal free, testing methods for chemicals. One such research initiative involved was Sens-it-iv (www.sens-it-iv.eu), a large EU-funded research project dedicated to develop and optimize in vitro (‘out of body’) test strategies that could reduce or replace animal testing for sensitization studies.
In 2005, lead by Malin Lindstedt, at the Department of Immunotechnology at Lund University, Sweden, and professor Carl Borrebaeck, Vice Chancellor of Lund University and sub-coordinator of Sens-it-iv, Lindstedt’s group joined with Sens-it-iv.
At this time there were no animal free methods for testing chemical compounds for their potential to induce allergies on the market.
One of the key partners involved with the project was the European Centre for the Validation of Alternative Methods (ECVAM) at the Joint Research Centre in Ispra, Italy.
As a result of this co-operation, Lindstedts’ group in Lund has now developed a completely animal free method based on human cells grown in the lab.
Dr. Ann-Sofie Albrekt, the bioinformatician in the team, has done a substantial amount of the analyses for the Sens-it-iv project and the further development of the animal free assay, named GARD (Genomic Allergen Rapid Detection).
As an internationally-renowned centre for research and education, Lund University is highly regarded for its research in cutting-edge fields including nanotechnology, translational cancer research, and stem cell biology.
Dr. Albrekt is currently focusing on two key areas: looking for new biomarkers in cancer studies, as well as performing important research on allergens.
"Worldwide, more and more people are suffering from allergies, which means that this area has become an important health concern," says Dr. Albrekt. "As a scientist, I am interested to find out why otherwise harmless compounds can often elicit an adverse immune response in humans."
Making sense of important data
Dr. Albrekt is currently using sophisticated data analysis software, called Qlucore Omics Explorer, to help her to get the most value out of the data being produced by this research.
"Although gene expression studies are proving invaluable to the study of allergens, the amount of data that is produced by these experiments is enormous," she says. "As a result, it is impossible to derive any real biological meaning from these findings unless sophisticated data algorithms are used to help interpret this data effectively."
For this reason, most of the software that has been designed for use in this area has mainly focused on the ability to handle increasingly vast amounts of data, which means that the role of the scientist/researcher has been largely set aside.
As a result, a lot of data analysis has been passed on to bioinformaticians and biostatisticians. However, in most cases, this model has several drawbacks, since it is typically the scientists themselves who know the most about biology.
"In our studies, we are dealing with very large amounts of data, sometimes between 10 and 100 million data points, which we tend to view as graphics” says Dr. Albrekt. “With other software, these graphics would take a long time to appear, but with the latest data analysis tools, the information is presented instantly. As a result, we can be much more creative with our theories, as we can easily test any number of hypotheses in rapid succession."
With the freedom, speed and flexibility provided by this approach, it is now possible to evaluate and test a number of different scenarios and hypothesis in a very short time, and to fully understand the data being examined.
This technique makes it possible for researchers to combine very large amounts of data, and therefore to conduct analysis in ways that were simply not possible before.
The latest technological advances in this area are making it much easier for researchers to compare the vast quantity of genomic data generated, to test different hypotheses, and to explore alternative scenarios within seconds.
Not only that, but the latest generation of data analysis software is also helping the scientists (biologists, MD, and so on) to regain control of the analysis and to realize the true potential of gene expression profiling.
According to Dr. Albrekt, her own research efforts will continue to focus on both the allergen studies, as well as on the ongoing cancer research within CREATE Health, which is a strategic centre for translational cancer research.
"In terms of the work we did in the Sens-it-iv project, I am very confident that our success in creating an animal free test system will significantly reduce the number of animals sacrificed for safety testing and as well as increasing the accuracy of the safety tests performed " she says. "This project will therefore be of substantial benefit to all European citizens, and that goal continues to motivate me to make new discoveries in this area."
The assay development work resulting in the GARD assay will be presented in the doctoral thesis defense of Henrik Johansson on June 5th at Lund University.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
New Algorithms Help Extract 3-D Biological Structure from Limited DataNews
CAMERA researchers capitalize on their Multi-Tiered Iterative Phasing approach to determine molecular structure of proteins and viruses from X-ray free electron laser data.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018